NLRP3 and Patent ductus arteriosus: Subsequent inhibition of NLRP3 signaling or mice deficient in inflammasome components (NLRP3, ASC, or caspase-1) showed immunogenic reprogramming of innate and adaptive immunity within the TME and were protected against PDA (81).